Form 8-K - Current report:
SEC Accession No. 0001193125-22-173861
Filing Date
2022-06-14
Accepted
2022-06-14 16:30:36
Documents
12
Period of Report
2022-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d317882d8k.htm   iXBRL 8-K 27654
  Complete submission text file 0001193125-22-173861.txt   149401

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pyxs-20220613.xsd EX-101.SCH 2864
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE pyxs-20220613_lab.xml EX-101.LAB 17980
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pyxs-20220613_pre.xml EX-101.PRE 11264
6 EXTRACTED XBRL INSTANCE DOCUMENT d317882d8k_htm.xml XML 3345
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 221015232
SIC: 2834 Pharmaceutical Preparations